BACKGROUND: The influence of human papillomavirus (HPV) status on survival for patients with very advanced inoperable oropharyngeal SCC treated with radiochemotherapy (RCT) was studied. METHODS: Patients received either 69.2 Gy with concomitant boost (ccb) or 70 Gy conventionally fractionated (cf), weekly paclitaxel 40 mg/m(2), and carboplatin area under the concentration-time curve (AUC) 1. Tumor was analyzed for the presence of high-risk HPV-DNA using polymerase chain reaction (PCR) and direct DNA sequencing. p16-expression, survivin, and epidermal growth factor receptor (EGFR) expression were evaluated by immunohistochemistry and influence on survival was calculated. RESULTS: Of 52 patients, 25.0% were HPV positive and 75.0% HPV negative. The 2-year progression-free survival (PFS) was 70.1% for p16-positive patients and 37.1% for p16-negative patients (p = .005). The 3-year overall survival (OS) rate was 43.9% for all patients and did not significantly differ between the groups. Neither survivin nor EGFR expression influenced PFS or OS significantly. CONCLUSIONS: HPV status influences PFS in patients with advanced, nonresectable tumor stages but not OS. Additional risk factors seem to have a stronger influence on survival than HPV status.
BACKGROUND: The influence of human papillomavirus (HPV) status on survival for patients with very advanced inoperable oropharyngeal SCC treated with radiochemotherapy (RCT) was studied. METHODS:Patients received either 69.2 Gy with concomitant boost (ccb) or 70 Gy conventionally fractionated (cf), weekly paclitaxel 40 mg/m(2), and carboplatin area under the concentration-time curve (AUC) 1. Tumor was analyzed for the presence of high-risk HPV-DNA using polymerase chain reaction (PCR) and direct DNA sequencing. p16-expression, survivin, and epidermal growth factor receptor (EGFR) expression were evaluated by immunohistochemistry and influence on survival was calculated. RESULTS: Of 52 patients, 25.0% were HPV positive and 75.0% HPV negative. The 2-year progression-free survival (PFS) was 70.1% for p16-positive patients and 37.1% for p16-negative patients (p = .005). The 3-year overall survival (OS) rate was 43.9% for all patients and did not significantly differ between the groups. Neither survivin nor EGFR expression influenced PFS or OS significantly. CONCLUSIONS:HPV status influences PFS in patients with advanced, nonresectable tumor stages but not OS. Additional risk factors seem to have a stronger influence on survival than HPV status.
Authors: Xu Qian; Steffen Wagner; Chenming Ma; Annekatrin Coordes; Julia Gekeler; Jens P Klussmann; Michael Hummel; Andreas M Kaufmann; Andreas E Albers Journal: J Cancer Res Clin Oncol Date: 2014-04-27 Impact factor: 4.553
Authors: Jolien Heukelom; Olga Hamming; Harry Bartelink; Frank Hoebers; Jordi Giralt; Teresa Herlestam; Marcel Verheij; Michiel van den Brekel; Wouter Vogel; Nick Slevin; Eric Deutsch; Jan-Jakob Sonke; Philippe Lambin; Coen Rasch Journal: BMC Cancer Date: 2013-02-22 Impact factor: 4.430
Authors: Rachel F Shenker; Nelson H May; Joshua D Waltonen; Jae Paul Yang; Stacey S O'Neill; Bart A Frizzell; Kathryn M Greven; Ryan T Hughes Journal: Head Neck Pathol Date: 2021-02-22
Authors: C Grønhøj Larsen; M Gyldenløve; D H Jensen; M H Therkildsen; K Kiss; B Norrild; L Konge; C von Buchwald Journal: Br J Cancer Date: 2014-02-11 Impact factor: 7.640
Authors: Georgios Psychogios; Konstantinos Mantsopoulos; Abbas Agaimy; Kathrin Brunner; Elisabeth Mangold; Johannes Zenk; Heinrich Iro Journal: Biomed Res Int Date: 2014-03-31 Impact factor: 3.411